Alex Dominguez is the Chief Investment Officer for Unicoin, the official cryptocurrency of Unicorn Hunters, the groundbreaking platform that connects investors seeking funding with millions of investors worldwide and provides viewers with access to invest in transparent pre-IPO opportunities. Unicoin is a next-generation coin that is designed to be asset-backed and dividend-paying. In his role, Alex is responsible for driving investment in the coin prior to its launch on major crypto exchanges in 2023.
Alex is a seasoned sales executive with experience in the pharmaceutical and biotech industries, having held leadership roles at Sanofi Aventis and Abbott Labs. Most recently, he helped launch the world’s first FDA-approved treatment for peanut allergies while working for startup Aimmune Therapeutics, which was acquired by Nestle Health Sciences in 2020. Previously, he held management, marketing, and sales roles at Teva Pharmaceuticals, one of the largest manufacturers of generic pharmaceuticals. While at Teva, he helped grow the worldwide market share of various respiratory and CNS drugs, such as QVAR and AJOVY.
Alex holds an MBA degree from Barry University with a concentration in Public Administration. He earned his undergraduate degree in Finance and International Business from Florida International University in 1991. He also held Series 3, 7, 24, 30, and 63 FINRA securities licenses in the past and has five years of experience as a retail stockbroker in the U.S. equities market.